NFT
PTGX icon

Nan Fung Trinity’s Protagonist Therapeutics PTGX Stock Holding History

Nan Fung Trinity’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.9M Sell
160,670
-20,000
-11% -$1.77M 1.86% 18
2025
Q4 		$15.8M Buy
180,670
+35,778
+25% +$2.93M 1.25% 35
2025
Q3 		$9.63M Buy
144,892
+9,842
+7% +$559K 0.96% 39
2025
Q2 		$7.46M Buy
+135,050
New +$6.48M 0.89% 39

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Nan Fung Trinity's PTGX Position: Q1 2026 in Review

Nan Fung Trinity reduced its Protagonist Therapeutics (PTGX) stake by 11% in Q1 2026, selling an estimated $1.77M and leaving 160,670 shares worth $16.9M. The position accounts for 1.86% of the portfolio, ranked #18.

Nan Fung Trinity first reported a position in PTGX in Q2 2025 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Nan Fung Trinity held 160,670 shares of Protagonist Therapeutics worth $16.9M as of Q1 2026.
  • Nan Fung Trinity sold 20,000 Protagonist Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Protagonist Therapeutics made up 1.86% of Nan Fung Trinity's portfolio in Q1 2026, its #18 holding.
  • Nan Fung Trinity first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Nan Fung Trinity's 13F filing for Q1 2026, filed 5 May 2026.